Noting that "Spanish news outlet" Intereconomia has talked about a deal between Amgen (AMGN) and Alexion (ALXN) in at least three separate articles over the last month, claiming most recently that Amgen is now "in the final stretch to buy Alexion" for $200 per share, Mizuho analyst Salim Syed said in a note to investors yesterday that "the concept of this happening doesn't sound too crazy" though the validity of the source can be debated. An Amgen deal for Alexion would be highly accretive and his previous M&A investor survey earlier this year showed Alexion was the deal that the buyside voted for the most, said Syed, who has a Neutral rating on Amgen shares.